2,618 results on '"Hassan A"'
Search Results
2. Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank
3. Clinical and functional spectrum of RAC2-related immunodeficiency
4. Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease
5. Donor plasmacytoid dendritic cells limit graft-versus-host disease through vasoactive intestinal polypeptide expression
6. Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank
7. Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency
8. Bone marrow regeneration requires mitochondrial transfer from donor Cx43-expressing hematopoietic progenitors to stroma
9. Unveiling Gender Disparities: Female Authorship in Pivotal Trials for US Food and Drug Administration (FDA)-Approved Novel Chimeric Antigen Receptor T-Cell Therapies
10. Treatment of Critical Bleeding Events in Patients with Immune Thrombocytopenia: A Systematic Review
11. Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
12. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies
13. Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. 'the TOTAL Trial'
14. Phase II clinical trial evaluating Abatacept in patients with steroid-refractory chronic graft versus host disease
15. Identification and Interpretation of Clinically Relevant Somatic Variants from Whole-Genome Sequencing Data
16. Phase II clinical trial evaluating Abatacept in patients with steroid-refractory chronic graft versus host disease
17. Clinical and Molecular Characteristics of ETV6 Mutated Myeloid Malignancies
18. Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol
19. Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms
20. Molecular Patterns Identify Distinct Subclasses of Myeloid Neoplasia
21. The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy
22. Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?
23. Clinical and Biological Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (t-ALL) Following Multiple Myeloma Are Distinct in Comparison to t-ALL Following Other Cancers
24. MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis
25. The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification
26. Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy
27. Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy
28. Lectins from opportunistic bacteria interact with acquired variable-region glycans of surface immunoglobulin in follicular lymphoma
29. Two types of BCR interactions are positively selected during leukemia development in the Eβ-TCL1 transgenic mouse model of CLL
30. Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b
31. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
32. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
33. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
34. Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?
35. CPX-351 for Blast-Phase Myeloproliferative Neoplasm (MPN-BP): Mayo Clinic Experience in 10 Consecutive Patients
36. Patients with B Cell Malignancy That Lacked Immune Response to Sars-Covid-2 Vaccination Mount Antibody Response Following Actual Sars-Covid-2 Infection: Potential to Improve Vaccination Strategy
37. Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
38. Impact of Race on the Mortality of Thrombotic Thrombocytopenic Purpura in the United States: A Population Study
39. Primary Analysis of a Pilot Study of Prophylactic Anakinra to Mitigate CAR T Cell-Associated Toxicity in Patients with Relapsed or Refractory Large B-Cell Lymphoma
40. Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm
41. Neighborhood Disadvantage, Insurance Status, and Molecular Profiling of Patients with Acute Myeloid Leukemia
42. Pharmacological Management of GI Bleed Secondary to Arteriovenous Malformations: A Systematic Review
43. Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
44. Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms
45. TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
46. MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis
47. Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival
48. Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"
49. Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms
50. Which Asparaginase Formulation Retained Higher VTE Incidence Risk in Post Treatment Adult Acute Lymphoblastic Leukemia? a Meta-Analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.